New Rezpegaldesleukin Data Supporting Long-term Durability and Disease Improvement in Patients with Alopecia Areata and Atopic Dermatitis at EADV Congress 2026

Nektar reported durable Phase 2b rezpegaldesleukin activity through 52 weeks in alopecia areata and atopic dermatitis, supporting advancement into pivotal trials. In alopecia areata, 75% (6/8) of patients maintained SALT ≤20 four months after stopping treatment and 63% (5/8) did so at six months, while SALT ≤10 responses increased from 7% at Week 52 to 19% after six months off treatment. In atopic dermatitis, EASI-100 responses rose from 4% to 22% with monthly maintenance dosing and from 9% to 18% with quarterly dosing; Nektar has initiated its third Phase 3 AD trial and plans to begin the 850-patient Phase 3 ZENITH AA study in early 2027.

Analysis

The relevant valuation change is not the maintenance data alone, but the emerging possibility that rezpegaldesleukin could be positioned as a treatment-with-remission rather than another chronic suppressive dermatology biologic. If pivotal data reproduce durable control on infrequent maintenance dosing, payer resistance and patient burden could be materially lower than for continuously dosed alternatives, supporting premium net pricing and a larger addressable population. That is strategically adverse at the margin to JAK-centric alopecia franchises—Eli Lilly (LLY), Pfizer (PFE) and Sun Pharma (SUNPHARMA)—but only after a multi-year read-through; none faces a near-term earnings impact.

The immediate NKTR reaction should be discounted because the most favorable alopecia durability figures derive from only eight off-treatment responders, while both extension cohorts are enriched for patients who remained on study and showed prior benefit. The central Phase 3 risk is therefore reproducibility in a broader, more treatment-experienced population, particularly since the pivotal alopecia endpoint is assessed at one year rather than on post-treatment remission. A second risk is financing: expanded late-stage programs increase cash burn before a value-inflecting registrational readout, creating dilution risk that can overwhelm clinical narrative over the next 6-18 months.

The non-obvious upside is platform optionality: concordant durability across two unrelated dermatology indications makes Treg stimulation more credible as a mechanism, potentially raising the value of the Type 1 diabetes program and pipeline rather than merely adding indication-specific NPV. Conversely, the market may be over-crediting quarterly dosing before seeing discontinuation, immunogenicity, infection, and durability outcomes in larger populations. The next 1-3 month catalyst is management’s disclosure of Phase 3 design, enrollment pace, cash runway, and statistical assumptions; absent a clearly funded path through major data, this remains a high-volatility development-stage equity rather than a core biotech long.

Key Decisions for Investors

• Maintain a tactical long bias in NKTR only after the post-call liquidity window, sized as a binary-risk biotech position (typically 50-100 bps). The setup supports a 1-3 month narrative rerating if management confirms runway through key Phase 3 milestones; exit on evidence of financing before a material catalyst or guidance implying slower enrollment.
• Do not underwrite the alopecia remission claim into base-case valuation until the company discloses the full off-treatment denominator, disposition, and confidence intervals. Treat any sharp conference-driven move as an opportunity to trim rather than chase because the durability sample is too small to independently validate differentiation.
• Establish an alert for a funded Phase 3 plan: cash balance, quarterly operating burn, trial cost, and expected next financing date are the gating data. If runway is less than roughly 18 months, prefer waiting for a financing-led dislocation before initiating NKTR exposure.
• Watch LLY, PFE, and SUNPHARMA only as longer-dated competitive hedges, not shorts: a meaningful threat requires Phase 3 confirmation of comparable efficacy plus less frequent maintenance and clean safety. The thesis is falsified if pivotal data show efficacy converging with existing JAK inhibitors or require ongoing frequent dosing.